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concomitantly with ESAs in 3/15 studies. One study concluded that ESAs were associ-
ated with lower direct costs after initiation of dialysis (compared to no treatment),
while another study demonstrated that ESAs were associated with lower HRU (when
treatment is adapted to achieve normal hemoglobin [Hb] levels). Six studies indicated
that aiming for higher Hb targets resulted in a higher medication burden and higher
other direct costs. The impact onHRU (e.g., hospitalizations) was inconsistent in two
studies. ESA treatment generally led to HRQoL improvements of uncertain clinical sig-
nificance (five studies). Compared to aiming for lower Hb targets, setting higher Hb
targets led to higher overall HRQoL across six studies.
CONCLUSIONS: The evaluable recent literature on renal anemia among DD patients
and related to cost and HRQoL was largely focused on ESAs, and only a limited number
of publications included iron as a treatment of interest. In spite of their higher phar-
macy costs, patients treated with ESAs had lower medical and overall costs relative to
non-treated patients. Although strategies aiming for high (vs. lower) Hb targets yielded
higher HRQoL, the increased risk of MACE associated with use of ESAs at high Hb tar-
gets mitigates their potential benefit. Additional research should be conducted to assess
the impact of alternative therapies on the economic and humanistic burden of renal
anemia.
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INTRODUCTIONANDAIMS:Hyporesponsiveness to erythropoiesis stimulating
agents (ESA) has emerged with respect to a poor renal and overall survival in patients
with chronic kidney disease (CKD). The BRIGHTEN study is a multicenter prospective
observational study conducted in the real world clinical setting in Japan to explore both
a responsiveness to Darbepoetin alfa (DA) and a resistance index to DA associated with
poor renal outcome and cardiovascular events in non-dialysis CKD patients. So, the
current study was aimed to investigate an initial responsiveness to DA and its contribu-
ting factors using the data from the BRIGHTEN study.
METHODS:Of 1941 patients enrolled on 168 facilities, 450 patients were excluded
mainly for the lack of hemoglobin (Hb) values at 12 weeks. A total of 1491 patients was
included in the current study and initial ESA response index (EResI) was defined as the
ratio of Hb changes over the 12 weeks after DA administration per total DA doses used
in that same period. First, initial EResI was investigated from the view point of number
of DA doses and total doses of DA. Furthermore, contributing factors to EResI were
analyzed by ANOVA.
RESULTS: Amean age was 70-years (Male, 58%). The prevalence of diabetic nephrop-
athy and nephrosclerosis was 26.5% and 24.3%, respectively. Creatinine and Hb levels
at DA initiation were 2.88mg/dl and 9.77g/dl, respectively. Themost frequent number
of DA doses during 12 weeks was 3 times (42%) followed by 4 (16%) and 6 times (14%)
with a wide distribution of total DA doses from 15 to 900lg. Initial EResI increased in
relation to the number of DA doses, whereas was not associated with a total DA doses
and even decreased in a total DA dose of> 180lg. 186 patients (12.5%) had no
response or even decreased in the Hb level at 12 weeks. Multivariate analysis showed
that sex, diabetes, iron supplementation, eGFR, Hb, CRP, NT-proBNP, proteinuria
were independently and significantly associated with initial EResI.
CONCLUSIONS:Non-responder to DAwas12.5% of non-dialysis CKD patients. Iron
deficiency, low Hb, high CRP, high NT-proBNP, and severe proteinuria were modifi-
able contributing factors associated with initial hyporesponsiveness to DA.
Furthermore, frequent administration of DA could effectively raise the Hb level.
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INTRODUCTIONANDAIMS:Many patients initiate hemodialysis (HD) with low
hemoglobin (Hgb) levels and receive intense therapy during the early HD period to
achieve Hgb targets. Management of anemia before the start of HDmay improve sur-
vival after dialysis start by avoiding the potential lingering harm of chronic anemia
and/or avoiding high doses of ESA and IV iron in the early months of HD. To test this
hypothesis, we investigated the association between low vs. target Hgb at HD start and
mortality through 1 year of HD among patients with target Hgb at 4months.
METHODS:We analyzed incident HD patients from 21 countries in phases 4-5 (2009-
2015) of the Dialysis Outcomes and Practice Patterns Study (DOPPS). Cox regression
was used to estimate the association between Hgbmeasured within 30 days (month 1)
of starting HD andmortality frommonth 4 throughmonth 12 among patients with
Hgb 10 g/dL at month 4. Models were stratified by DOPPS phase and country and
adjusted for potential confounders. IV iron and ESA dose over the first 90 days of HD
were added to the model in a sensitivity analysis because these factors may be on the
causal pathway between lowmonth 1Hgb and death after month 4.
RESULTS: The study population consisted of 4461 HD patients with Hgb 10 g/dL at
month 4; at month 1, 80% hadHgb< 11 g/dL and 53% hadHgb< 10 g/dL. Compared
to patients with Hgb<11 g/dL, patients with Hgb11 g/dL at month 1 were older,
more likely male, had higher albumin and lower TSAT, but did not have a lower burden
of comorbidities. Hgb at month 1 was inversely associated with first-year mortality
(adjusted HR for 1 g/dL higher Hgb¼ 0.89; 95%CI: 0.82-0.96) despite minimal differ-
ences in Hgb at month 4 (see Table, where Hgb is categorized). Patients with lower Hgb
at month 1 received greater ESA doses over the first 3 months of HD and achieved the
largest Hgb increases over these 3 months. In contrast, mean IV iron dose over the first
3 months varied much less by month 1 Hgb level. Additional adjustment for ESA and
IV iron doses over the first 3 months of HD hadminimal impact on the mortality HR
¼ 0.90 (95% CI: 0.82-1.00).
CONCLUSIONS: These results support our hypothesis that management of anemia
before the start of HDmay improve survival during the first year of HD treatment.
High doses of ESA and IV iron did not appear to explain the association between low
Hgb andmortality, though a more formal mediation analysis is required. A limitation
of this analysis is the lack of available data on pre-HD treatment with ESA or iron; we
also cannot rule out residual confounding due to better health status and/or pre-HD
care in patients who start HDwith higher Hgb.
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INTRODUCTIONANDAIMS: Erythropoiesis-stimulating agents (ESAs) are widely
used to treat anaemia in End Stage Renal Disease (ESRD) patients onmaintenance hae-
modialysis (HD). Factors influencing the ESA hypo-responsiveness (iron deficiency,
severe hyperparathyroidism, high C-reactive, malnutrition, medications. . .) are well
known. Chronic extracellular fluid overload (FO) is considered as a cause of hyperten-
sion, heart failure, andmortality in HD patients. However, to our knowledge no study
has addressed the relationship of FO and ESA hypo-responsiveness in HD patients.
This retrospective analysis of a clinical database (EuCliD5) aimed to evaluate the
impact of FO on ESA responsiveness in HD patients,
METHODS: This is a cross-sectional database study which included 3999 patients
treated by high-volume haemodiafiltration 3 times/week via double needle in 38
Portuguese FreseniusMedical NephroCare dialysis units in November 2017. FOwas
assessed using bioimpedance spectroscopy (body compositionmonitor - BCM
VR
device). Patients were considered to be overhydrated when relative fluid overload ratio
(RFO¼absolute fluid overload/extracellular volume) was15% inmen and13% in
women compared to healthy population. Patients with the following condition were
excluded: Cancer, polycystic kidney disease, moderate or severe liver disease, patients
in dialysis less than 3 andmore 120months, patients hospitalised in November 2017 or
when data were missing. All patients received epoetin beta subcutaneously as ESA and
IV iron sucrose for iron repletion.
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